DeepMed Research

Takeda Pharmaceutical Company Ltd

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Completed

Conditions: Von Willebrand Disease (VWD)

First Posted Date: 2022-03-03

Last Posted Date: 2023-08-31

Lead Sponsor: Takeda

Target Recruit Count: 102

Registration Number: NCT05265078

Locations: 🇩🇪
MVZ Gerinnungszentrum Hochtaunus, Bad Homburg vor der Höhe, Hessen, Germany

First-in-Human Study of TAK-280 in Participants With Solid Tumors

Phase 1

Active, not recruiting

Conditions: Unresectable Locally Advanced or Metastatic Cancer

Interventions: Drug: TAK-280

First Posted Date: 2022-02-02

Last Posted Date: 2025-03-30

Lead Sponsor: Takeda

Target Recruit Count: 69

Registration Number: NCT05220098

Locations: 🇺🇸
University of Arkansas For Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University of Minnesota - Masonic Cancer Center, Minneapolis, Minnesota, United States

and more 20 locations

A Chart Review Study of Adults With Advanced NSCLC

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2022-01-26

Last Posted Date: 2023-02-28

Lead Sponsor: Takeda

Target Recruit Count: 179

Registration Number: NCT05207423

Locations: 🇫🇷
CHU Strasbourg - Nouvel Hopital Civil, Strasbourg, Rhone, France
🇨🇦
University Health Network Princess Margaret Cancer Research Tower (PMCRT) The MaRS Centre, East Tower, Toronto, Ontario, Canada
🇫🇷
Centre Hospitalier de Saint-Quentin, Saint-Quentin cedex, Aisne, France

and more 27 locations

A Study of Vedolizumab in Adults With Crohn's Disease (CD)

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Other: No Intervention

First Posted Date: 2022-01-14

Last Posted Date: 2025-01-06

Lead Sponsor: Takeda

Target Recruit Count: 72

Registration Number: NCT05192863

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇮🇱
Sheba Medical Center, Ramat Gan, Israel
🇮🇹
ASST Fatebenefratelli Sacco, Milano, Italy

and more 7 locations

A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma

Phase 4

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Pomalidomide
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2022-01-10

Last Posted Date: 2022-05-03

Lead Sponsor: Takeda

Registration Number: NCT05183139

A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

Phase 1

Completed

Conditions: Sleep Apnea

Interventions: Drug: Placebo
Drug: Danavorexton

First Posted Date: 2022-01-06

Last Posted Date: 2022-12-02

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT05180890

Locations: 🇦🇺
Adelaide Institute for Sleep Health (AISH), Flinders University, Adelaide, Australia

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Phase 1

Active, not recruiting

Conditions: Kidney Disease
Glomerulonephritis

Interventions: Drug: Mezagitamab

First Posted Date: 2021-12-30

Last Posted Date: 2025-01-27

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT05174221

Locations: 🇸🇬
National University Hospital- Singapore, Singapore, Singapore
🇦🇺
Core Research Group, Milton, Queensland, Australia
🇨🇳
Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

and more 23 locations

A Study of TAK-103 in Adult with Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Biological: TAK-103

First Posted Date: 2021-12-21

Last Posted Date: 2024-12-03

Lead Sponsor: Takeda

Target Recruit Count: 2

Registration Number: NCT05164666

Locations: 🇯🇵
Hyogo College of Medicine Hospital, Nishinomiya, Hyogo, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Phase 3

Active, not recruiting

Conditions: Dravet Syndrome (DS)
Lennox Gastaut Syndrome (LGS)

Interventions: Drug: Soticlestat

First Posted Date: 2021-12-20

Last Posted Date: 2025-03-27

Lead Sponsor: Takeda

Target Recruit Count: 400

Registration Number: NCT05163314

Locations: 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Center For Neurosciences, Tucson, Arizona, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 112 locations

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Phase 3

Recruiting

Conditions: Coagulation Disorder

Interventions: Drug: SOC 4F-PCC
Drug: TAK-330

First Posted Date: 2021-12-14

Last Posted Date: 2024-12-19

Lead Sponsor: Takeda

Target Recruit Count: 328

Registration Number: NCT05156983

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
University of California Davis Health System, Sacramento, California, United States
🇺🇸
University of Louisville School of Medicine, Louisville, Kentucky, United States

and more 45 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy